NCT01062477已完成3 期
Safety and Immunogenicity of the Sanofi Pasteur's DTaP//PRP-T Combined Vaccine (ACTACEL) Versus Local DTaP and Hib Conjugate (Act-HIB) Monovalent Vaccine as a Three-dose Primary and Booster Vaccination in Healthy Infants in China
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 1,056
- 试验地点
- 2
- 主要终点
- Immunogenicity: To provide information concerning the immunogenicity of ACTACEL vaccine after primary and booster vaccination.
研究概览
简要总结
The purpose of this study is to assess the immunogenicity and safety of ACTACEL combined vaccine in support of registration of this product in China
Primary Objectives:
- To demonstrate that ACTACEL vaccine administered at 2, 3 and 4 months of age or at 3, 4 and 5 months of age is not inferior, in terms of seroprotection, to Wuhan's Diphtheria, Tetanus, acellular Pertussis (DTaP) and Haemophilus influenzae type b (Act-HIB) vaccine given concomitantly, for diphtheria, tetanus, and Polyribosyl Ribitol Phosphate (PRP) antigens, one month after the three-dose primary vaccination.
- To demonstrate the superiority, in terms of seroconversion, of ACTACEL vaccine administered at 2, 3 and 4 months of age or at 3, 4 and 5 months of age for Pertussis Toxoid (PT), Fimbriae types 2 and 3 (FIM2) and (FIM3) pertussis antigens, compared with Wuhan's DTaP and Act-HIB vaccines given concomitantly, one month after the three-dose primary vaccination.
Secondary Objectives:
- To describe the safety after administration of the study vaccines.
- To describe in each group the immunogenicity of the study vaccines one month after the primary vaccination and before and one month after the booster vaccination.
详细描述
Participants will receive a primary vaccination consisting of three doses of ACTACEL at either 2, 3, and 4 months of age or at 3, 4, and 5 months of age; or Wuhan DTaP and Act-HIB vaccines at 3, 4, and 5 months of age. All participants will receive a single booster dose at 18-20 months of age and will be followed up for one month after the last dose of study vaccine.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 60 Days 至 89 Days（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Aged 2 months on the day of inclusion
- •Born at full term pregnancy (≥ 36 weeks) with a birth weight ≥ 2.5 kg
- •Informed consent form signed by the parent(s) or legal representative
- •Participant and parent/legal representative able to attend all scheduled visits and to comply with all trial procedures
排除标准
- •Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination
- •Planned participation in another clinical trial during the present trial period
- •Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy since birth, or long-term systemic corticosteroids therapy
- •Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or to a vaccine containing any of the same substances
- •Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator
- •Receipt of blood or blood-derived products since birth that might interfere with the assessment of immune response
- •Receipt or planned receipt of any vaccine in the 4 weeks preceding or following any trial vaccination (except oral poliovirus (OPV), bacillus Calmette-Guérin (BCG), and Hepatitis B vaccines which cannot be given within 8 days before or after any study vaccination)
- •History of seizures
- •Known personal or maternal Human Immunodeficiency Virus (HIV), Hepatitis B (HB) surface antigen or Hepatitis C seropositivity
- •History of diphtheria, tetanus, pertussis or Haemophilus influenzae type b infection (confirmed either clinically, serologically or microbiologically)
- •Previous vaccination against diphtheria, tetanus, pertussis or Haemophilus influenzae type b disease with either the trial vaccine or another vaccine
- •Participant at high risk for diphtheria, tetanus, pertussis or Haemophilus influenzae type b infection during the trial
- •Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding inclusion contraindicating intramuscular vaccination
- •History of contraindication to vaccination with pertussis-containing vaccine
- •Febrile illness (axillary temperature ≥37.1°C) or moderate or severe acute illness/infection on the day of inclusion, according to Investigator judgment
- •Temporary contraindications that must be resolved before vaccination:
- •Acute febrile illness within the 72 hours preceding the vaccination, or temperature ≥37.1°C present at this visit
- •Any vaccination in the 4 weeks preceding the vaccination (except OPV, BCG, and hepatitis B vaccines which cannot be given within 8 days before or after any study vaccination)
- •Systemic corticosteroids therapy (prednisone or equivalent) for more than 2 consecutive weeks within the past 3 months
研究组 & 干预措施
Study Group 1
Experimental
Participants will receive ACTACEL vaccine at 2, 3, and 4 months of age.
干预措施: DTaP//PRP-T Combined Vaccine (Biological)
Study Group 2
Experimental
Participants will receive ACTACEL vaccine at 3, 4, and 5 months of age.
干预措施: DTaP//PRP-T Combined Vaccine (Biological)
Study Group 3
Active Comparator
Participants will receive Wuhan DTaP and Act-HIB vaccines concomitantly at 3, 4 and 5 months of age.
干预措施: DTaP Combined Vaccine and PRP-Tetanus Conjugate Vaccine (Biological)
结局指标
主要结局
Immunogenicity: To provide information concerning the immunogenicity of ACTACEL vaccine after primary and booster vaccination.
时间窗: One month post-vaccination
次要结局
- Safety: To provide information concerning the safety after primary and booster administration of ACTACEL vaccine.(0-7 days post-vaccination and entire study duration)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants.PoliomyelitisHaemophilus Influenzae Type BTetanusDiphtheriaPertussisNCT01214889Sanofi370
已完成
3 期
Sanofi Pasteur's Tdap Combined Vaccine as a Booster Versus Local DT Vaccine in Children or Versus Local Td Vaccine in Adolescents and Adults in China.TetanusDiphtheriaPertussisNCT01993173Sanofi Pasteur, a Sanofi Company1,440
已完成
1 期
An Investigational Combination Vaccine Given to People Who Are Not Infected With HIVHIV InfectionsNCT00027365National Institute of Allergy and Infectious Diseases (NIAID)84
已完成
1 期
Study of Colon GVAX and Cyclophosphamide in Patients With Metastatic Colorectal CancerMetastatic CancerColorectal CancerNCT00656123Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins9
已完成
1 期
Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non-pregnant Women 18-40 Years of Age.Infection by Streptococcus Group BNCT02459262Minervax ApS240